Reserved area

Credentials and contents in the EryDel “RESERVED AREA” are strictly confidential and the access is authorized only for the medical staff operating the EDS in the ATTeST study. The Content of the “RESERVED AREA” should not be copied, distributed or reproduced in whole or in part, nor distributed to any third party if not for the  training purpose of authorized EDS Operators. The Content of the “RESERVED AREA” is only for medically trained staff.

I Agree

2019-06-10

Luca Benatti, President and Chief Executive Officer, and Stan Musial, Chief Financial Officer, will participate in the JMP Life Sciences Conference on Wednesday, June 19, 2019, at the St. Regis New York. The Company is scheduled to present at the conference at 1:30.

» Download Press Release


2019-01-08

EryDel Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs.

» Download Press Release


2018-12-17

EryDel received the 2018 most innovative company Startup Italia Award on occasion of the Open Summit 2018 that took place in Milano on 17 December.


2018-11-12

EryDel Appoints Stan Musial as Chief Financial Officer

» Download Press Release


2018-10-15

EryDel appoints Ronan Gannon as Chief Commericial Officer

» Download Press Release


2018-06-04

EryDel-Orphan Technologies signing a licensing and supply agreement

» Download Press Release


2018-05-14

EryDel to present at the UBS Global Healthcare Conference 2018

» Download Press Release


2018-04-24

EryDel Raises Euro 26.5 Million in Financing

» Download Press Release


2018-02-16

EryDel Appoints Guenter R Janhofer, MD, as Chief Medical Officer

» Download Press Release


2017-03-06

EryDel announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study

» Download Press Release


2016-01-07

EryDel Consortium gains Euro 6 million Funding for development of EDS for the treatment of Ataxia Telangiectasia

» Download Press Release


2015-05-19

Long term benefit of erytrocyte-delivered dexamathasone in Ataxia Telangiectasia

» Download Press Release


2015-05-11

EryDel expands Series B financing to 29.5M

» Download Press Release


2014-02-20

Phase II results in Ataxia Telangiectasia published in Orphanet Journal of Rare Diseases

» Download Press Release


2013-09-17

EryDel selected as one of the top five candidates in 2013 EuropaBio Most Innovative EU Biotech SME Award

» Download Press Release


2013-09-05

Enzyme-loaded erythrocytes restore normal blood concentrations of Phenylalanine in a mouse model of Phenylketonuria (PKU)

» Download Press Release


2013-07-31

EryDel SpA Completes €15 Million Series B financing

» Download Press Release


2013-06-17

EryDel SpA Announces EMA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia

» Download Press Release


2013-04-29

EryDel announces US IND approval for EryDex

» Download Press Release


2013-02-12

Data on Magnetic Red Blood Cells (RBCs) as new contrast agents for Magnetic Resonance Imaging (MRI) applications to be presented at SPIE Medical Imaging Annual Meeting 2013

» Download Press Release


2012-10-29

Journal of Biological Chemistry publication highlights molecular mechanism for EryDex effect on Ataxia Telangiectasia-mutated (ATM) protein

» Download Press Release


2012-07-30

EryDel SpA Announces FDA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia.

» Download Press Release


2012-06-01

EryDel announces the appointment of the Company CEO.

» Download Press Release


2012-02-29

EryDel announces Positive Results with EryDex in patients with Ataxia Telangiectasia.
Significant benefit seen on Primary and Secondary end-points.

» Download Press Release


2010-09-13

EryDel has CE Marked its New Medical Devices for automatic encapsulation of Drugs into Human Autologous Red Blood Cells

» Download Press Release

Where We Are

×